References


ARUP offers a comprehensive menu to assess patients with kidney stone disease. **Calculi (stone) testing specializes in two areas** that provide valuable information to determine appropriate treatment and course of patient care:

1. Assessing and monitoring the risk of stone formation (urine studies)
2. Evaluating stone composition

**Epidemiology**

- Approximately 11 percent of adults in the United States will develop kidney stones in their lifetime. These rates double in patients with a family history of stones.
- Men are two to three times more likely than women to experience kidney stones.
- The five-year recurrence rate is reported to be as high as 50 percent after the first episode.
- Incidence of this disease is rising and estimated to cost $5.3 billion per year in healthcare dollars.

**Benefits of Calculi Testing at ARUP**

- ARUP has designed efficient urine panels that assess stone-forming risk, monitor the course of therapy, and reduce testing expenses. (ARUP test codes 2008771, 2008708, 0020843)
- ARUP has developed in-house technology for stone processing which reduces errors and decreases turnaround time.
- A full stone analysis with a photo is available through ARUP’s enhanced reporting system.

**Available Laboratory Testing**

<table>
<thead>
<tr>
<th>test code</th>
<th>test name</th>
</tr>
</thead>
<tbody>
<tr>
<td>0099460</td>
<td>Calculi (Stone) Analysis</td>
</tr>
<tr>
<td>2005231</td>
<td>Calculi (Stone) Analysis with Photo</td>
</tr>
<tr>
<td>0081105</td>
<td>Cystinuria Panel (rare genetic disease) To diagnose or rule out cystinuria.</td>
</tr>
<tr>
<td>0081106</td>
<td>Cystine Quantitative, Urine For monitoring treatment of patients previously diagnosed with cystinuria.</td>
</tr>
</tbody>
</table>

ARUP has designed efficient urine panels that assess stone-forming risk, monitor the course of therapy, and reduce testing expenses.